Biotech | 08 July 2025
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
New research labs and process development services to enable next generation therapeutics
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Subscribe To Our Newsletter & Stay Updated
